Orient Pharma Co (ROCO:4166) Beneish M-Score: -2.72 (As of Jul. 07, 2026)


ROCO:4166 Orient Pharma Co Ltd ROCO:4166
56 GF Score
Price NT$27.20
GF Value NT$45.09
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co Beneish M-Score?

Orient Pharma Co ROCO:4166 +5.02% 56 Beneish M-Score is -2.72 as of Jul. 07, 2026. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 910 Drug Manufacturers companies, Orient Pharma Co ranks better than 69.89% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.72 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Orient Pharma Co's Beneish M-Score or its related term are showing as below:

ROCO:4166' s Beneish M-Score Range Over the Past 10 Years
Min: -3.44   Med: -3.08   Max: -2.72
Current: -2.72

During the past 13 years, the highest Beneish M-Score of Orient Pharma Co was -2.72. The lowest was -3.44. And the median was -3.08.


Orient Pharma Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co Beneish M-Score Chart

Orient Pharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2.72

Orient Pharma Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -2.26 0.00 -2.72

ROCO:4166 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Pharma Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's Beneish M-Score falls into.


ROCO:4166
56GF Score
Orient Pharma Co Ltd ROCO:4166
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Pharma Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Orient Pharma Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8012+0.528 * 0.9437+0.404 * 0.7759+0.892 * 1.1452+0.115 * 0.9737
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0362+4.679 * -0.051532-0.327 * 0.434
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$265 Mil.
Revenue was 441.808 + 316.122 + 325.546 + 316.902 = NT$1,400 Mil.
Gross Profit was 265.514 + 176.412 + 183.573 + 165.222 = NT$791 Mil.
Total Current Assets was NT$1,259 Mil.
Total Assets was NT$2,938 Mil.
Property, Plant and Equipment(Net PPE) was NT$875 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$136 Mil.
Selling, General, & Admin. Expense(SGA) was NT$444 Mil.
Total Current Liabilities was NT$187 Mil.
Long-Term Debt & Capital Lease Obligation was NT$180 Mil.
Net Income was 91.829 + 47.264 + 18.774 + 50.571 = NT$208 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 101.013 + 63.596 + 68.943 + 126.306 = NT$360 Mil.
Total Receivables was NT$288 Mil.
Revenue was 319.221 + 300.617 + 327.03 + 275.948 = NT$1,223 Mil.
Gross Profit was 175.03 + 140.779 + 175.404 + 160.346 = NT$652 Mil.
Total Current Assets was NT$728 Mil.
Total Assets was NT$2,521 Mil.
Property, Plant and Equipment(Net PPE) was NT$903 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$136 Mil.
Selling, General, & Admin. Expense(SGA) was NT$374 Mil.
Total Current Liabilities was NT$487 Mil.
Long-Term Debt & Capital Lease Obligation was NT$238 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(264.595 / 1400.378) / (288.375 / 1222.816)
=0.188945 / 0.235829
=0.8012

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(651.559 / 1222.816) / (790.721 / 1400.378)
=0.532835 / 0.564648
=0.9437

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1259.138 + 874.563) / 2938.353) / (1 - (728.426 + 902.6) / 2520.582)
=0.273845 / 0.352917
=0.7759

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1400.378 / 1222.816
=1.1452

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(135.721 / (135.721 + 902.6)) / (135.607 / (135.607 + 874.563))
=0.130712 / 0.134242
=0.9737

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(443.73 / 1400.378) / (373.934 / 1222.816)
=0.316864 / 0.305797
=1.0362

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((179.813 + 187.1) / 2938.353) / ((238.051 + 487.25) / 2520.582)
=0.12487 / 0.287751
=0.434

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(208.438 - 0 - 359.858) / 2938.353
=-0.051532

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Orient Pharma Co has a M-score of -2.72 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.72 mean?
Orient Pharma Co (ROCO:4166) has a Beneish M-Score of -2.72 as of Jul. 07, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Orient Pharma Co and its competitors. According to the industry distribution chart, Orient Pharma Co ranks #274 out of 910 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Orient Pharma Co's Beneish M-Score too high?
Orient Pharma Co's current Beneish M-Score is -2.72. Based on the distribution chart, Orient Pharma Co ranks #274 out of 910 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #274 out of 910 companies for Beneish M-Score. This puts Orient Pharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Orient Pharma Co and its competitors. Orient Pharma Co's current Beneish M-Score is -2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Beneish M-Score is -2.72. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Beneish M-Score is -2.72 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • Beneish M-Score: -2.72
  • GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score

Get the complete analysis for ROCO:4166

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.20
Price
NT$45.09
GF Value